Cilostazol and Endothelial Progenitor Cell (EPISODE)
Myocardial Infarction, Acute
About this trial
This is an interventional treatment trial for Myocardial Infarction, Acute focused on measuring Endothelial progenitor cell, Myocardial infarction, acute, Platelets, Cilostazol
Eligibility Criteria
Inclusion Criteria:
- naïve AMI
- undergoing successful coronary stent implantation
Exclusion Criteria:
- high-risk patients for thrombotic event;
- a history of active bleeding or bleeding diatheses;
- contraindication to antiplatelet therapy;
- hemodynamic or electrical instability;
- oral anticoagulation therapy;
- left ventricular ejection fraction < 30%;
- leukocyte count < 3,000/mm3 and/or platelet count < 100,000/mm3;
- AST or ALT > 3 times the respective the upper limit;
- serum creatinine level > 3.5 mg/dL;
- stroke within 3 months;
- pregnancy;
- non-cardiac disease with a life expectancy < 1 year;
- any patients not tolerable or suitable for coronary intervention; and
- inability to follow the protocol
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
CILO group
Placebo group
Intervention: Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room. After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence. For the CILO group, cilostazol-SR 200 mg daily was added to dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily). Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial. Drug: Cilostazol-SR, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily.
Intervention: Suspected patients with AMI were loaded with 600-mg clopidogrel and 300-mg aspirin in the emergency room. After 3 to 5 days post-PCI (before discharge), patients were randomly allocated to the CILO group or the placebo group (1:1 fashion) based on a computer-generated randomization sequence. In the Placebo group, placebo tablet was administered on top of dual antiplatelet therapy with aspirin (100 mg daily) and clopidogrel (75 mg daily). Study drug is maintained for 30 days. Double blinded, Randomized, Placebo controlled Trial. Drug: Placebo, Tablet, 200mg, once daily. Astrix, Capsule, 100mg, once daily. Plavix, tablet, 75mg, once daily.